Humana backs move to limit extra payments from home-visit diagnoses - report

Published 05/06/2025, 10:56
© Reuters.

Investing.com -- Health insurance company Humana (NYSE:HUM) has expressed support for a legislative move that could reduce billing practices which currently allow insurers to earn billions in additional payments, according to the Wall Street Journal on Thursday.

The proposed legislative change would put a cap on the profitable payments that insurance companies can receive from diagnoses made by nurse practitioners during home visits to enrollees.

Humana communicated its willingness to back these new restrictions in a one-page policy overview that was shared with congressional staffers, the report said.

The current billing practices involve nurse practitioners visiting millions of enrollees in their homes, and the diagnoses made during these visits can lead to substantial extra payments for insurers.

The proposed limitations aim to curtail these practices, potentially saving billions of dollars.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.